long-term protection of kidney function as demonstrated for ACE inhibitors and some calcium channel Background. The objective of this study was to examine the effects of angiotensin II receptor blocker losar-blockers [1] . The reduction in albumin excretion is mainly explained by the blood pressure lowering effect tan versus the calcium channel blocker amlodipine on proteinuria, renal haemodynamics, glomerular sieving of an antihypertensive drug. However, for some classes of antihypertensive drugs, it have been demonstrated and tubular function in hypertensive patients with nondiabetic nephropathy.
Introduction
of the patients were classified as chronic glomerulonephritis based on biopsy findings. Patients were selected on the basis Short-term evaluation of antihypertensive drugs for of increased urinary albumin excretion rate above 200 mg/min renoprotection is often based on the therapy effect on on two occasions, mild to moderate hypertension with diathe surrogate endpoint albumin excretion [1] . This stolic blood pressure 90-119 mmHg, and creatinine clearance short-term effect in reducing proteinuria may reflect a between 20 and 80 ml/min.
Study protocol
were not initiated until the urine osmolality was below 200 m/osm/kg. The study followed a two period crossover design. It consisted
The sieving function was estimated by clearances of neutral of a 4-week run-in period without medication, followed by dextrans with different sizes. After the priming dose of inulin, a 4-week active treatment period with losartan or amlodipine, a dose of 130 mg/kg of Rheomacrodex (Pharmacia, Uppsala, then a 6-week placebo washout period, and lastly a 4-week Sweden) was infused i.v. over the course of 15 min. crossover period with the alternate treatment. All antihyperRheomacrodex contains various-size dextrans, 90% ranging tensive treatment and any drugs known to affect blood between 10 000 and 80 000 dalton, corresponding to a hydropressure, renal haemodynamics, tubular function or glomerdynamic or viscosity radius of 27 to 75 Å . The size of ular function (in particular non-steroidal anti-inflammatory globular proteins was expressed as Stokes radius or as drugs and acetylsalicylic acid ) were discontinued prior to the viscosity radius (hydrodynamic radius) are closely depicted run-in period, except for diuretics (furosemide 40-80 mg) at by the viscosity radius of dextran. [13] . However, proteins constant dosage necessary for edema treatment. Prior to the and dextran do not lie on a common calibration curve when run-in period, five patients had been using calcium channel Stokes radius is used as size parameter for dextran [13] . We blockers (3 nifedipine GITS, 2 amlodipine), 7 patients ACE therefore used the measure of viscosity radius as a measure inhibitors (three enalapril, four lisinopril ), one patient aof globular proteins in solution in the calculation rather than blocker (doxazosin) and 3 patients were without antihyperthe rather than Stokes radius [7, 13] . The viscosity radius is tensive medication. At the end of the run-in period, patients calculated from the formula R h =0.271×M r 0.498 whereas were randomized to one of the two sequences for active Stokes radius is given by R St =0.33×M r 0.463 [13] . The differtreatment. Losartan treatment was started at 50 mg once ence appears from the formulas used for calculation and daily and amlodipine at 5 mg once daily. After 1 week of does not represent difference in the dextran method. The active treatment, if satisfactory blood pressure control was clearance of dextrans of different sizes was calculated after not achieved (DBP decreased by 10 mmHg from baseline size separation by size-exclusion chromatography in serum and/or DBP fall to <85 mmHg), titration was carried out and urine samples on a XK 16/100 macro-column with by doubling of the dose to losartan 100 mg once daily or Sephacryl S-300 HR gel packed to a bed height of 93-cm amlodipine 10 mg once daily at the 1-3 week visits.
(Pharmacia LKB Biotechnology AB, Uppsala, Sweden). The At study entry and completion, a complete physical examsample size applied on the column was 1 ml both for serum ination and ECG were obtained. Throughout the study, the and undiluted urine, each separated into 20-30 fraction and patients were seen at weekly intervals at the Renal Research measured the range of 30-60 Å of viscosity radius (each Center at the National Hospital, University of Oslo. Blood fraction contains dextrans within a range of 2 Å radius). samples and duplicate 24-h urine samples were collected at Dextrans were hydrolyzed with sulfuric acid and measured the end of the run-in period and at the end of the two active by the anthrone methods as described by Scott and Melvin treatment periods. Renal clearance was performed as [14] . The column was calibrated using a dextran sample described below on the last day of the run-in period and the possessing a broad molecular mass distribution, i.e. with a last day of each treatment period. Blood pressure was mass average (M w ) of 72 300 or number-average molecular measured in an identical fashion throughout the study. The mass (M n ) of 30 000 giving a polydispersity, M w /M n of 2.4, actual blood pressure reading was the mean value of the last which had been determined by size-exclusion chromatotwo of three recordings taken with a standard sphygmomanography (Pharmacia LKB Biotechnology AB, Uppsala, meter with the patient seated for at least 5 min. Diastolic Sweden). The fractional dextran clearance data were calcublood pressure was recorded as the disappearance of lated by a data program (Sec-soft; © L. Hagel ) with a simple Korotkoff sound (phase 5).
spreadsheet (Excel ) [13] .
Renal clearance studies Biochemical analyses
Renal clearance examinations were performed on the last day of the run-in period and on the last day of each treatment Serum sodium, potassium, chloride, bicarbonate, urea and urine sodium and potassium were measured by an autoanaperiod. The evening before each clearance study, the subjects ingested 18 mmol of lithium citrate (LithionitR) in order to lyser (Beckman Astra, Sweden). Serum and urine lithium was determined by atomic absorption. Haemoglobin and obtain a plasma lithium concentration of about 0.3 mmol/l. Two intravenous cannulas were inserted, one for the infusion white blood count were determined by coulter counter.
Commercial radioimmunoassay kits determined plasma renin of inulin and para-amino-hippurate (PAH ) and the other in the opposite arm for repeat blood sampling. The subjects activity and plasma aldosteron. Inulin concentration was determined according to Schreiner [15] . PAH was determined were initially hydrated orally with 20 ml/kg of tap water, thereafter the patients drank 250 ml of tap water every according to Smith [16 ] . Serum and urine albumin was determined with a radioimmunoassay kit (Pharmacia AB, 30 min to maintain adequate urine flow. A priming dose of 30 ml of inulin (10% solution) and 7 ml of PAH (20% Uppsala, Sweden). Total protein in serum and urine were measured by the biuret method. Serum and urine bsolution) was infused over 10 min followed by a continuous infusion of inulin and PAH designed to maintain blood levels 2-microglobulin were assayed by a commercial radioimmunoassay kit (Pharmacia AB, Uppsala, Sweden). Urine samples of 200-300 mg/l and 20-40 mg/l, respectively. For the continuous infusion 13 ml of PAH (20% solution) and 54 ml of for b-2-microglobulin were stored at pH >6. Normal range for b-2-microglobulin in our laboratory is in serum 1010 to inulin (10% solution) were mixed with 920 ml of 0.9% NaCl, the infusion rate was 150-200 ml/h. Following a 60-min 2170 mg/l and normal excretion in urine is between 0.044 and 0.285 mg/24 h. Creatinine in serum and urine were equilibration period, four carefully timed urine collections of 25 to 30 min each were obtained by spontaneous voiding. determined by a rate dependent modification of the Jaffe reaction using a creatinine analyser, Beckman creatinine Blood pressure and blood samples for measurements of electrolytes, lithium, inulin and PAH were obtained at the analyser model 2. Urinary N-acetyl-beta-glucosaminidase line to the end of either treatment period. Losartan therapy was as expected associated with an increase in Statistical analyses renin activity confirming the compliance during the study. Serum aldosteron was unchanged from baseline Efficacy data was based on all patients with data at baseline during either treatment. Serum potassium increased and both active treatment periods. The blood pressure and significantly (P<0.05) during losartan treatment.
laboratory efficacy data were analyzed by the appropriate methods for two-period cross-over clinical trials, using changes from baseline ( last observation at the end of the Effects on blood pressure wash-out period ), with untransformed data for blood pressures and log transformed data for laboratory data. [19] .
The mean of two observations taken at two consecutive days The blood pressure measurements are summarized in was used for 24-h urine collection results. The mean of four Table 2 . Sixty-nine percent of patients who received observations taken during the 6-h ambulatory blood pressure both treatments were titrated upwards to the higher measurement was used for clearance measurements.
dose of losartan (100 mg once daily) and 77% were T-tests were used to assess the presence of period and titrated upward on amlodipine (10 mg once daily).
sequence effects, the between-treatment analyses using
Mean arterial blood pressure decreased from within-patient (crossover) differences, and the within-124±13 mmHg at baseline to 113±10 mmHg treatment changes from baseline using pooled data from (P<0.01) on losartan and to 114±10 mmHg on amloboth active treatment periods. The between-and withintreatment analyses were adjusted for a period effect. If a dipine (P<0.01). Diastolic blood pressure was reduced significant period (P<0.05) or sequence (P<0.10) effect was from 105±12 mmHg to 96±11 mmHg on losartan detected, an additional analysis was performed using only (P<0.01) and to 96±12 mmHg on amlodipine data from the first treatment period.
(P<0.01) after 4 weeks of treatment. The mean Untransformed and transformed data were reported as decrease in DBP was similar on both treatments at mean values at baseline and on-therapy. All statistical com-each relative week. Losartan also significantly reduced parisons were based on two-sided tests. Statistical significance systolic blood pressure from a baseline value of was declared if the probability value P was <0. 05 
General parameters
Mean arterial blood pressure 124±13 113±10** 114±10** (mm Hg) were no significant difference in systolic blood pressure 37±250 ml/min) and no significant change in filtration fraction. level between losartan and amlodipine treatment.
Effects on albumin and protein excretion Effect on renal markers
The baseline values and the effects of both drugs on Urinary albumin excretion rate significantly (P<0.01) decreased from a baseline value of 3510±2586 mg/24 h renal markers are shown in Table 5 . The urinary excretion of markers for proximal tubular function, NAG to 2684±2051 mg/24 h (27.7% reduction from baseline) on losartan, Table 3 . Amlodipine therapy and ALP, were pathologically elevated in the patients in our study. The proximal markers ALP and NAG increased albumin excretion to 3748±3355 mg/24 h (n.s.). Mean albumin/creatinine ratio significantly were unchanged during either drug period as compared to baseline. The low molecular protein b-2-(P<0.01) decreased from 273±221 mg/mmol at baseline to 215±131 mg/mmol during losartan therapy, microglobulin is also excreted in an abnormal high rate in these patients consistent with a proximal tubular whereas there was no change from baseline on amlodipine therapy. dysfunction in patients with nephropathy. The excretion of b-2-microglobulin tended to decrease during Urinary total protein excretion rate significantly decreased (P<0.01) from a baseline value of losartan therapy and increase during amlodipine therapy, although the changes were not statistically 4.0±2.8 g/24 h to 3.1±2.3 g/24 h on losartan (24.3% reduction from baseline) and increased to significant. Amlodipine significantly increased lithium clearance from 18±10 ml/min to 23.0±11 ml/min (P= 4.5±3.8 g/24 h on amlodipine at week 4. The mean protein 24-h excretion rate was significantly lower <0.05), whereas losartan therapy was without effect on lithium clearance. Uric acid excretion was not (P<0.05) on losartan compared with amlodipine.
changed during treatment periods. Neither drug affected the excretion of kallikrein. Sodium excretion was
Effect on renal haemodynamics
unchanged from baseline in either drug period.
The data are summarized in Table 4 . Effective renal
Effect of sieving of neutral dextrans during the plasma flow ( ERPF ) increased from a baseline value
clearance periods of 192±153 ml/min to 204±172 ml/min on losartan while GFR (inulin clearance) slightly decreased from 37±24 ml/min to 36±287 ml/min. This resulted in a Figure 1 shows the mean clearance values of dextrans slightly, but significant lower filtration fraction of relative to that of inulin in the 30-60 Å ranges of 21.2±10.2 during losartan therapy compared to base-dextran viscosity radii. Each collected fraction correline filtration fraction of 22.8±9.3. Amlodipine did sponds to a range of 2 Å . No significant change was not change ERPF from baseline (192±153 ml/min vs found at any point between the fractional dextran 196±155 ml/min) nor GFR (37±24 ml/min vs clearance curve during baseline compared to either the losartan or amlodipine period. and reduced renal function Mosconi et al. [5] failed to demonstrate an effect of size-selectivity by perindopril. The observed antialbuminuric effect of losartan in this study is consistent with results from previous studies that angiotensin II receptor blockers may reduce proteinuria [8] [9] [10] . Gansevort et al. [9] indicated that the effect could be due to a fall in intraglomerular pressure and/or changes in glomerular basement membrane characteristics. The unchanged dextran clearance and the reduction in filtration fraction during losartan therapy supports the findings of Gansevort et al. [9] that haemodynamic factor may contribute to the albuminuric sparing effect during losartan treatment. However, with the relatively small [21]. Losartan had no effect on kallikrein excretion in our study consistent with a lack of effect on the amlodipine was without effect. The novel approach in kinin-kallikrein system. This could explain the modest this study was the use of dextran clearance to effect on filtration fraction. However, similar systemic characterize pore size selectivity during losartan or and renal haemodynamic effects of losartan and ACE amlodipine therapy in man.
inhibitors suggest that the antiproteinuric effects may Effects of angiotensin II receptor blockers on glomer-be mediated by interference in the renin-angiotensin ular sieving have been suggested from experimental system, rather than the kinin-kallikrein system [1, 22] . studies [11, 12] . The study of Mayer et al. [11] in the The decline in albumin excretion during losartan was remnant rat model demonstrated that angiotensin II somewhat less than reported in the studies of receptor blockade restored glomerular size-selectivity, Gansevort et al. [8, 9] . The antihypertensive medication but not the defect in glomerular charge-selectivity. used by the patients prior to baseline might have Remuzzi et al. [12] showed that long term treatment influenced baseline albumin excretion as six of the of diabetic rats with losartan prevented the loss of patients in our study were using ACE inhibitors. sieving function of the glomerular membrane as However, this is probably of minor importance as assessed by Ficoll fractional clearance. One could argue discontinuation of ACE inhibitor therapy for 28 days that the reduction in proteinuria in our study could be has been associated with a rebound of albumin excreattributed to a change in charge selectivity as the tion to baseline [23] . dextran clearance measures only size selectivity.
Changes in proximal tubular reabsorptive mechanHowever, the experimental studies indicate that the isms by direct tubular effects of drugs might affect improvement of sieving function obtained by losartan albumin reabsorption as albumin is extensively reabis probably mediated by restoration of size selectivity sorbed in the proximal tubules [24] . We have previously [11, 12] . The contribution of losartan to the observed shown that the different effects of enalapril and nifedipantiproteinuric effect is probably not mediated by ine on tubular function might explain the opposite alterations in glomerular size selectivity, at least not in effects of the drugs on albumin excretion [25] . Tubular non-diabetic patients with advanced renal impairment function was also assessed in this study. NAG and and macroalbuminuria.
ALP are intracellular and brush-border enzyme The effect on sieving function during ACE inhibition markers, respectively, which may indicate derangement also varies. In patients with non-diabetic renal disease of proximal tubular function [26, 27] . Lithium clearand well preserved renal function, Remuzzi et al. [3] ance and b-2-microglobulin may be used to assess demonstrated that enalapril improved glomerular sizeproximal tubular function [25] . All patients in our selectivity. However, in a recent report Hemmelder study had a proximal tubular dysfunction defined as et al. [6 ] were unable to show any effect of trandolapril an increased excretion of the proximal markers NAG, on dextran clearance in non-diabetic patients with ALP and beta-2 microglobulin. Although losartan has proteinuria. Morelli et al. [2] documented that enalapbeen shown previously to have some renal tubular ril improved size selectivity in IDDM patients with effects [28] , in our study losartan did not significantly macroalbuminuria and well preserved renal function.
change urinary excretion of uric acid, ALP, NAG, bRemuzzi et al. [4] using enalapril reported similar 2-microglobulin nor lithium clearance. As long as the findings on glomerular permselectivity in patients with different markers for proximal tubular function IDDM and more advanced renal dysfunction. However, in NIDDM patients with overt proteinuria remained unchanged during losartan therapy, changes
